Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Gallagher

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Gut|July 14, 1999
Nuclear factor kappaB in liver diseaseN J Gallagher, L S Young
Immunology Today|November 18, 1998
CD40 and epithelial cells: across the great divideL S Young, A G Eliopoulos, N J Gallagher, et al.
The Journal of Biological Chemistry|May 29, 1999
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 productionA G Eliopoulos, N J Gallagher, S M Blake, et al.
Molecular Pathology : MP|April 16, 2002
CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretionN J Gallagher, A G Eliopoulos, A Agathangelo, et al.
Molecular and Cellular Biology|July 13, 2000
CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamilyA G Eliopoulos, C Davies, P G Knox, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Gut|July 14, 1999
Nuclear factor kappaB in liver diseaseN J Gallagher, L S Young
Immunology Today|November 18, 1998
CD40 and epithelial cells: across the great divideL S Young, A G Eliopoulos, N J Gallagher, et al.
The Journal of Biological Chemistry|May 29, 1999
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 productionA G Eliopoulos, N J Gallagher, S M Blake, et al.
Molecular Pathology : MP|April 16, 2002
CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretionN J Gallagher, A G Eliopoulos, A Agathangelo, et al.
Molecular and Cellular Biology|July 13, 2000
CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamilyA G Eliopoulos, C Davies, P G Knox, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Pageof 1